Citigroup Inc Genmab A/S Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Genmab A/S stock. As of the latest transaction made, Citigroup Inc holds 19,793 shares of GMAB stock, worth $407,537. This represents 0.0% of its overall portfolio holdings.

Number of Shares

19,793

Previous 23,069 14.2%

Holding current value

$407,537

Previous $579,000 16.75%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$23.84 - $28.48 $78,099 - $93,300	-3,276 Reduced 14.2%	19,793 $482,000
Q2 2024 Aug 12, 2024	BUY	$25.13 - $30.27 $112,808 - $135,882	4,489 Added 24.16%	23,069 $579,000
Q1 2024 May 10, 2024	BUY	$26.43 - $32.77 $43,741 - $54,234	1,655 Added 9.78%	18,580 $555,000
Q4 2023 Feb 09, 2024	SELL	$27.94 - $35.44 $129,082 - $163,732	-4,620 Reduced 21.44%	16,925 $538,000
Q3 2023 Nov 09, 2023	BUY	$35.27 - $42.24 $453,678 - $543,333	12,863 Added 148.16%	21,545 $759,000
Q2 2023 Aug 10, 2023	BUY	$37.4 - $42.94 $120,876 - $138,782	3,232 Added 59.3%	8,682 $330,000
Q1 2023 May 11, 2023	SELL	$34.88 - $43.22 $688,287 - $852,860	-19,733 Reduced 78.36%	5,450 $205,000
Q4 2022 Feb 09, 2023	BUY	$33.8 - $47.06 $691,919 - $963,365	20,471 Added 434.44%	25,183 $1.07 Million
Q3 2022 Nov 10, 2022	SELL	$31.52 - $373.61 $2,017 - $23,911	-64 Reduced 1.34%	4,712 $151,000
Q2 2022 Aug 10, 2022	SELL	$26.83 - $38.57 $15,829 - $22,756	-590 Reduced 11.0%	4,776 $156,000
Q1 2022 May 12, 2022	BUY	$30.95 - $39.68 $247 - $317	8 Added 0.15%	5,366 $194,000
Q4 2021 Feb 10, 2022	SELL	$35.87 - $47.12 $1.26 Million - $1.65 Million	-35,016 Reduced 86.73%	5,358 $213,000
Q3 2021 Nov 10, 2021	BUY	$41.55 - $48.72 $1.68 Million - $1.97 Million	40,374 New	40,374 $1.76 Million

Others Institutions Holding GMAB

# of Institutions

236

Shares Held

52.5M

Call Options Held

10.2K

Put Options Held

25.5K

View Full List

About GENMAB A/S

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

More about GMAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account